Breakthrough Inhaled Live Biotherapeutic
Changes in microbial signatures of the lungs and airways are associated with worsening chronic respiratory disease and persistent inflammation.
Alveolus Bio has used over a decade of pulmonary microbiome research and clinical data to inform development of novel inhaled live biotherapeutics (LBPs) that address fibroblast dysfunction and neutrophilic inflammation.
Alveolus Bio’s preclinical programs include assets for:
- Idiopathic Pulmonary Fibrosis (IPF) – orphan disease
- Chronic Obstructive Pulmonary Disease (COPD) –15M patients in the US
- Non-Cystic Fibrosis Bronchiectasis (NCFBE) – rare disease